Combination treatment for TP53-mutated AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug (axatilimab) combined with two standard chemotherapy drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has a TP53 mutation. The goal is to see if this combination helps control the cancer better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have AML or a related bone marrow condition (MDS) with a TP53 mutation or deletion (a specific genetic change).
- Your disease must be either newly diagnosed, or it has not responded to first treatment or has come back after first remission.
- You must be in generally good health, with a performance status score of 60 or higher (meaning you can care for yourself and do most daily activities).
- You must not have an active uncontrolled infection, HIV, or active hepatitis B or C.
- You must not have another active cancer that is currently being treated.
- You must not have serious heart, liver, or kidney problems, and no history of pancreatitis or muscle inflammation.
- You must not have had a stem cell transplant within the past 3 months, and you must not have graft-versus-host disease (GVHD) that requires immunosuppressive treatment.
- Your leukemia must not have spread to the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (hydroxychloroquine, decitabine, and venetoclax) for people with acute myeloid leukemia (AML) that is either hard to treat or very high-risk. The goal is to see if this combination can help control the leukemia and what side effects it may cause.
This study tests a new drug called ATRN-119 combined with decitabine for people with AML or higher-risk MDS that have a TP53 mutation. The goal is to see if the combination is safe and effective.
This trial tests a new drug, rezatapopt, combined with azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. It is only for people whose cancer cells have a specific change in a gene called TP53 (the Y220C mutation). The goal is to see if this combination can help control the disease.
This trial tests a new combination of two drugs (bortezomib and CPX-351) for people newly diagnosed with a specific type of AML that has a TP53 gene change. The goal is to see if this combination is safe and works better than standard treatment.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
This trial tests a combination of three drugs (tagraxofusp, azacitidine, and venetoclax) for people newly diagnosed with a type of acute myeloid leukemia (AML) that has developed after treatment with certain prior drugs (hypomethylating agents). The goal is to see if this combination is safe and effective.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.